Rectal Ketamine Administration: Uses in Pediatric and Palliative Care

Overview

Rectal administration of ketamine involves delivering the drug via the rectum, where it is absorbed through the rectal mucosa into the bloodstream. While this route is far less common than intravenous, intramuscular, or oral/sublingual administration, it has a well-established role in specific clinical contexts — particularly pediatric sedation and palliative care — where other routes may be impractical or poorly tolerated.

Rectal ketamine is not a standard treatment modality for psychiatric indications such as depression or PTSD. Its use is largely confined to situations where patients cannot take medications by mouth, intravenous access is difficult or unavailable, and a relatively rapid onset of action is needed.

Pharmacokinetics

Bioavailability

The rectal bioavailability of ketamine is approximately 25 to 30 percent, which is comparable to sublingual administration and somewhat higher than oral (swallowed) ketamine (17 to 24 percent). This intermediate bioavailability reflects the dual absorption pattern of rectal drug delivery:

• Lower rectum: Drugs absorbed from the lower portion of the rectum enter the inferior and middle rectal veins, which drain into the systemic circulation via the internal iliac veins, largely bypassing the liver and avoiding first-pass metabolism
• Upper rectum: Drugs absorbed from the upper rectum enter the superior rectal vein, which drains into the portal system and subjects the drug to hepatic first-pass metabolism

Because drug distribution within the rectum is variable, the extent of first-pass avoidance is inconsistent, leading to greater bioavailability variability compared to IV or IM routes.

Onset and Duration

• Onset of action: 10 to 20 minutes, faster than oral administration (20 to 45 minutes) but slower than IV (immediate) or IM (3 to 5 minutes)
• Peak plasma concentration: Typically reached within 20 to 45 minutes
• Duration of clinical effect: 60 to 120 minutes for sedation; analgesic effects may persist longer
• Half-life: The elimination half-life remains approximately 2 to 3 hours, consistent with other routes

Metabolism

Once absorbed, rectal ketamine undergoes the same metabolic pathway as other routes. The primary metabolite is norketamine, formed via N-demethylation by hepatic CYP3A4 and CYP2B6 enzymes. The proportion of drug subject to first-pass metabolism depends on the absorption site within the rectum, as described above.

Clinical Applications

Pediatric Sedation

Rectal ketamine has its most established role in pediatric medicine. Young children — particularly those under age 5 — may be unable or unwilling to take oral medications, may have difficult intravenous access, and may become extremely distressed by injections. Rectal administration provides a non-invasive route that avoids needles and does not require patient cooperation.

Common pediatric applications include:

• Procedural sedation: Brief procedures such as laceration repair, fracture reduction, imaging studies (CT or MRI), and burn dressing changes
• Preoperative sedation: Administered before surgery to reduce anxiety and facilitate separation from parents
• Emergency department use: When rapid sedation is needed and IV access has not yet been established

Typical pediatric dosing for rectal ketamine ranges from 5 to 10 mg/kg, substantially higher than IV doses (1 to 2 mg/kg for sedation) to compensate for the lower bioavailability. The drug is typically administered as a solution or suppository.

Palliative and End-of-Life Care

Rectal ketamine has an important role in palliative medicine, particularly for patients who:

• Cannot swallow due to advanced illness, nausea, or oropharyngeal dysfunction
• Have limited or no intravenous access
• Are receiving home-based hospice care where IV administration is impractical
• Experience refractory pain that has not responded to conventional opioid therapy

In palliative settings, ketamine is often used as an adjuvant analgesic for severe, refractory pain — particularly pain with a neuropathic component. The NMDA receptor antagonism provided by ketamine can help address opioid-resistant pain and reduce central sensitization that develops in advanced disease states. For more on ketamine's pain applications, see ketamine for chronic pain.

Veterinary Medicine

It is worth noting that rectal ketamine administration is also used in veterinary medicine for sedation of small animals and wildlife where injection is hazardous or impractical. While not directly relevant to human clinical care, veterinary pharmacokinetic data has contributed to the understanding of rectal ketamine absorption.

Formulations

Solutions

The most common rectal ketamine formulation is a liquid solution, which can be administered using a small syringe (without a needle) or a rectal catheter. Standard injectable ketamine solution (typically 50 or 100 mg/mL) is commonly used, diluted to an appropriate volume. The solution is gently instilled 2 to 4 centimeters into the rectum.

Suppositories

Compounded ketamine suppositories are available from compounding pharmacies and offer the advantage of a solid dosage form that is easier to retain. Suppositories are typically formulated in a cocoa butter or polyethylene glycol base and can be prepared in precise doses. They may be preferred for palliative care patients receiving repeated dosing at home.

Gels

Some compounding pharmacies prepare ketamine in a gel base for rectal administration. Gel formulations may provide more consistent mucosal contact and absorption compared to liquid solutions, though comparative bioavailability data is limited.

Administration Technique

Proper technique is important for consistent absorption and patient comfort:

1. Position: The patient should be placed in the left lateral decubitus (left side lying) position, which optimizes drug retention and distribution within the rectum
2. Volume: Keep the administered volume as small as practical (generally <10 mL in adults, proportionally less in children) to minimize the urge to expel
3. Depth of insertion: Insert the delivery device 2 to 4 centimeters in adults (less in children) to target the lower rectum, which offers better first-pass avoidance
4. Retention: The patient should remain in position for at least 10 to 15 minutes after administration to allow adequate absorption
5. Timing: The rectum should ideally be empty at the time of administration. Recent bowel movements or enemas may affect absorption

Advantages

• Non-invasive: No needles required, which is particularly valuable in pediatric and palliative care
• Does not require patient cooperation: Can be administered to unconscious, sedated, or uncooperative patients
• No oral intake needed: Suitable for patients who cannot swallow or who are actively vomiting
• Partial first-pass avoidance: Better bioavailability than fully swallowed oral ketamine
• Home administration: Practical for use in home hospice settings without clinical infrastructure

Limitations

• Variable absorption: Bioavailability is less predictable than IV or IM administration due to variable rectal blood flow, stool presence, and positioning of the drug within the rectum
• Patient acceptance: Some patients and families may find rectal administration uncomfortable or culturally unacceptable
• Dose precision: The variable bioavailability makes precise dose-response relationships more difficult to predict than with IV administration
• Rectal pathology: Patients with rectal inflammation, hemorrhoids, or recent rectal surgery may have altered absorption or experience discomfort
• Limited psychiatric use: Rectal administration has not been studied or adopted as a treatment route for depression, anxiety, or other psychiatric conditions treated with ketamine

Comparison with Other Routes

For a broader comparison of ketamine administration methods, see our IV vs oral vs nasal comparison.

Safety Considerations

Rectal ketamine carries the same general side effect profile as other routes of administration, including:

• Dissociative experiences — less pronounced at analgesic doses than at psychiatric or anesthetic doses
• Nausea and vomiting — less common with rectal than oral administration since the GI tract is not directly involved
• Increased salivation — particularly relevant in pediatric patients
• Cardiovascular stimulation — transient increases in heart rate and blood pressure

Monitoring requirements depend on the clinical context and dose. Procedural sedation doses in children require standard sedation monitoring (pulse oximetry, vital signs, level of consciousness assessment). Analgesic doses in palliative care may require less intensive monitoring, depending on the clinical setting and goals of care.

For a comprehensive review of ketamine side effects, see what are ketamine side effects?.

Summary

Rectal ketamine administration occupies a specialized niche in clinical practice, serving primarily as a practical alternative route when oral, IV, and IM administration are not feasible. Its primary applications are in pediatric procedural sedation — where it spares children from needle-related distress — and in palliative care, where it provides analgesic benefits to patients who can no longer take medications by mouth. While its bioavailability and absorption consistency are inferior to parenteral routes, rectal ketamine fills a genuine clinical need in situations where other options are limited.

References

• Malinovsky JM, et al. Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children. British Journal of Anaesthesia, 1996 — Pharmacokinetic comparison of ketamine routes in children
• Pediatric Procedural Sedation — American Academy of Pediatrics — Guidelines for sedation in pediatric settings
• WHO Model List of Essential Medicines — World Health Organization — Ketamine as an essential medicine, including use in resource-limited settings
• Palliative Care Use of Ketamine — National Institutes of Health (NIH) — Overview of ketamine in palliative pain management
• Yanagihara Y, et al. Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharmaceutics and Drug Disposition, 2003 — Comparative pharmacokinetic data across administration routes